310
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study

, , , , , ORCID Icon, , , , ORCID Icon, , , , , , & show all
Pages 625-636 | Received 24 Feb 2023, Accepted 02 Jun 2023, Published online: 19 Jun 2023

References

  • Holgate ST, Djukanović R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35(4):408–416. doi:10.1111/j.1365-2222.2005.02191.x
  • Global Initiative for Asthma. Global strategy for asthma management and prevention revised 2014; 2014. Available from: https://ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf. Accessed July 28, 2022.
  • Lee JK, Amin S, Erdmann M, et al. Real-world observational study on the characteristics and treatment patterns of allergic asthma patients receiving omalizumab in Canada. Patient Prefer Adherence. 2020;14:725–735. doi:10.2147/PPA.S248324
  • Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019;394(10196):407–418. doi:10.1016/S0140-6736(19)31147-X
  • Global Asthma Network. The global asthma report 2018; 2018. Available from: www.globalasthmanetwork.org. Accessed July 12, 2022.
  • Wang P, Wang L, Ni Q, Shi G. Factors of high asthma expenditure in China: an 1-year retrospective study. Value Health. 2018;21:S104. doi:10.1016/j.jval.2018.07.788
  • Schatz M, Rosenwasser L. The allergic asthma phenotype. J Allergy Clin Immunol. 2014;2(6):645–648.
  • Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol. 2003;112(2):252–262. doi:10.1067/mai.2003.1595
  • Mao D, Tang R, Wu R, et al. Prevalence trends in the characteristics of patients with allergic asthma in Beijing, 1994 to 2014. Medicine. 2017;96:22.
  • Platt-mills TAE. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001;164:51–55.
  • Omalizumab [package insert]. South San Francisco, CA: Genentech, Inc; 2021. Available from: www.fda.gov/medwatch. Accessed June 06, 2023.
  • Omalizumab 75 mg Solution. Summary of product characteristics (SPC) - (eMC); 2021. Availabe from: https://www.medicines.org.uk/emc/product/5327/ampc#gref. Accessed August 18, 2022.
  • Xolair (omalizumab). Data on file. Safety update. Period covered; 2018.
  • Li J, Kang J, Wang C, et al. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized Phase III study. Allergy Asthma Immunol Res. 2016;8(4):319–328. doi:10.4168/aair.2016.8.4.319
  • Chan J. Novartis’ asthma therapy Xolair gets approval in China; 2017. Available from: https://www.spglobal.com/marketintelligence/en/news-insights/trending/ygigsltbpjsgzlzabvyzfq2. Accessed July 3, 2022.
  • Lloyd A, Turk F, Leighton T, Canonica W. Psychometric evaluation of global evaluation of treatment effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J Med Econ. 2007;10(3):285–296. doi:10.3111/13696990701478856
  • Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma quality of life questionnaire. Eur Respir J. 1999;14:32–38. doi:10.1034/j.1399-3003.1999.14a08.x
  • Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in children with asthma. Qual Life Res. 1996;5(1):35–46. doi:10.1007/BF00435967
  • Zhang M, Jin M, Zhou X, et al. Effectiveness of omalizumab in patients with severe allergic asthma: a retrospective study in China. Respir Med. 2021;186:106522. doi:10.1016/j.rmed.2021.106522
  • Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the “real-world” effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151. doi:10.1016/j.rmed.2013.04.017
  • Bhutani M, Yang WH, Hébert J, De Takacsy F, Stril JL. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX observational study. PLoS One. 2017;12(8):e0183869. doi:10.1371/journal.pone.0183869
  • Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2(5):544–552.e2. doi:10.1016/j.jaip.2014.02.011
  • Adachi M, Kozawa M, Yoshisue H, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term post-marketing study in Japan. Respir Med. 2018;141:56–63. doi:10.1016/j.rmed.2018.06.021
  • Di Bona D, Fiorino I, Taurino M, et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study. Respir Med. 2017;130:55–60. doi:10.1016/j.rmed.2017.07.013